title: Alterations in Ca2+ transport ATPase and P-glycoprotein expression can mediate resistance to thapsigargin.
abstract: Resistance to the intracellular Ca2+ pump inhibitor thapsigargin (TG) is associated with overexpression of both Ca2+ transport ATPase and the multidrug resistance (mdr) transporter P-glycoprotein (pgp). This is supported by increased resistance to TG following transfection of a functional pgp1 cDNA, and reversal of TG resistance with known inhibitors of pgp function. However, pgp is unlikely to represent the only mechanism of resistance to TG. Cell lines selected for high levels of resistance to TG (250-fold) show only a 3.7-fold increase in pgp expression and a 2-fold increase in cross-resistance to other drugs of the mdr class. Overexpression of endogenous Ca2+ transport ATPase may represent a second mechanism of resistance to TG. Increased Ca2+ ATPase expression (3-fold) is seen in cells made resistant to TG, and TG resistance increases with the transfection of a specific Ca2+ ATPase cDNA into DC-3F cells. If these transfectants are then made resistant to TG, both the endogenous Ca2+ ATPase and the exogenously transfected Ca2+ ATPase become overexpressed. These studies suggest that while TG may be a substrate for pgp, acquired resistance to TG can involve alterations in both pgp and Ca2+ ATPase expression. Additional, as yet unidentified, mechanisms of resistance may be involved in resistance to TG.
authors.affiliation: University of Maryland Cancer Center, Baltimore, Maryland 21201.
authors.forename: J C
authors.initials: JC
authors.lastname: Gutheil
authors.forename: S R
authors.initials: SR
authors.lastname: Hart
authors.forename: C P
authors.initials: CP
authors.lastname: Belani
authors.forename: P W
authors.initials: PW
authors.lastname: Melera
authors.forename: A
authors.initials: A
authors.lastname: Hussain
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000818:Animals; D001386:Azides / Q000378:metabolism; D000252:Calcium-Transporting ATPases / Q000037:antagonists & inhibitors / Q000096:biosynthesis*; D002352:Carrier Proteins / Q000096:biosynthesis* / Q000378:metabolism; D002455:Cell Division; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D003078:Colchicine / Q000633:toxicity; D006224:Cricetinae; D003412:Cricetulus; D018076:DNA, Complementary / Q000378:metabolism; D003609:Dactinomycin / Q000633:toxicity; D003630:Daunorubicin / Q000633:toxicity; D004095:Dihydropyridines / Q000378:metabolism; D004351:Drug Resistance; D015870:Gene Expression; D008168:Lung; D008562:Membrane Glycoproteins / Q000096:biosynthesis* / Q000378:metabolism; D008939:Mitotane / Q000494:pharmacology*; D005810:Multigene Family; D013379:Substrate Specificity; D013729:Terpenes / Q000378:metabolism / Q000633:toxicity*; D019284:Thapsigargin; D014162:Transfection; D014750:Vincristine / Q000633:toxicity
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D001386:Azides; D002352:Carrier Proteins; D018076:DNA, Complementary; D004095:Dihydropyridines; D008562:Membrane Glycoproteins; D013729:Terpenes; D003609:Dactinomycin; D014750:Vincristine; C041130:azidopine; D019284:Thapsigargin; D008939:Mitotane; D000252:Calcium-Transporting ATPases; D003078:Colchicine; D003630:Daunorubicin